Clinical Trial

Liposomal Bupivacaine for Pain After Lumbar Fusion

Completed Phase 4
View on ClinicalTrials.gov →
Summary
Spine surgery often causes severe postoperative pain. Currently, our hospital routinely uses ropivacaine for local infiltration analgesia (lasting 6-8 hours). This study evaluates liposomal bupivacaine, a novel long-acting local anesthetic providing up to 72 hours of pain relief, in patients undergoing posterior lumbar spine surgery. Through a randomized controlled design, we will compare the two drugs' effects on pain control within 72 hours and opioid consumption. Both regimens are guideline-recommended and safe.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-09-05; most recent amendment 2026-06-30.
Status change: Recruiting → Completed 2026-06-30
Status change: Not Yet Recruiting → Recruiting 2025-09-20
Trial Details
NCT Number NCT07171125
Lead Sponsor Min Li
Conditions Postoperative Acute Pain, Lumbar Degenerative Diseases
Enrollment 204 participants
Start Date 2025-09-20
Primary Completion 2026-02-28 (estimated)
Study Completion 2026-03-03 (estimated)
Updated on ClinicalTrials.gov 2026-07-01